MX2023006677A - Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). - Google Patents
Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme).Info
- Publication number
- MX2023006677A MX2023006677A MX2023006677A MX2023006677A MX2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A MX 2023006677 A MX2023006677 A MX 2023006677A
- Authority
- MX
- Mexico
- Prior art keywords
- macular degeneration
- amd
- related macular
- compositions
- treating dry
- Prior art date
Links
- 208000011325 dry age related macular degeneration Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124695P | 2020-12-11 | 2020-12-11 | |
| PCT/US2021/062850 WO2022125925A1 (en) | 2020-12-11 | 2021-12-10 | Compositions for treating dry age-related macular degeneration (amd) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006677A true MX2023006677A (es) | 2023-06-27 |
Family
ID=81974688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006677A MX2023006677A (es) | 2020-12-11 | 2021-12-10 | Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240009168A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4259129A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023553414A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230118158A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116867488A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021396380A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200346A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303592A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006677A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022125925A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015116923A1 (en) | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| ES3063712T3 (en) | 2017-05-15 | 2026-04-20 | Cognition Therapeutics Inc | Compositions for treating neurodegenerative diseases |
| ES2969373B2 (es) | 2022-10-14 | 2025-02-06 | Igen Biolab Group Ag | Composicion obtenida de lisados de microorganismos probioticos para uso en el tratamiento y/o prevencion de las enfermedades degenerativas del ojo |
| WO2025122753A2 (en) * | 2023-12-08 | 2025-06-12 | Cognition Therapeutics, Inc. | Compositions and methods for the treatment of niemann-pick disease |
| CN117945980A (zh) * | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| EP1635805A4 (en) * | 2003-06-12 | 2007-08-08 | Ms Science Corp | SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT |
| US7829562B2 (en) * | 2003-06-12 | 2010-11-09 | M's Science Corporation | Sigma ligands for neuronal regeneration and functional recovery |
| GB0718737D0 (en) * | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
| BRPI0919920A2 (pt) * | 2008-10-22 | 2016-02-16 | Acucela Inc | compostos para tratamento de doenças e desordens oftálmicas |
| US20110269779A1 (en) * | 2008-11-18 | 2011-11-03 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| US20140378460A1 (en) * | 2011-08-25 | 2014-12-25 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
| WO2015116923A1 (en) * | 2014-01-31 | 2015-08-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| ES3063712T3 (en) * | 2017-05-15 | 2026-04-20 | Cognition Therapeutics Inc | Compositions for treating neurodegenerative diseases |
| KR20220142477A (ko) * | 2020-02-13 | 2022-10-21 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법 |
-
2021
- 2021-12-10 CN CN202180091728.8A patent/CN116867488A/zh active Pending
- 2021-12-10 IL IL303592A patent/IL303592A/en unknown
- 2021-12-10 MX MX2023006677A patent/MX2023006677A/es unknown
- 2021-12-10 WO PCT/US2021/062850 patent/WO2022125925A1/en not_active Ceased
- 2021-12-10 AU AU2021396380A patent/AU2021396380A1/en active Pending
- 2021-12-10 US US18/253,071 patent/US20240009168A1/en active Pending
- 2021-12-10 JP JP2023534245A patent/JP2023553414A/ja active Pending
- 2021-12-10 KR KR1020237023169A patent/KR20230118158A/ko active Pending
- 2021-12-10 CA CA3200346A patent/CA3200346A1/en active Pending
- 2021-12-10 EP EP21904483.1A patent/EP4259129A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230118158A (ko) | 2023-08-10 |
| AU2021396380A1 (en) | 2023-06-22 |
| CA3200346A1 (en) | 2022-06-16 |
| CN116867488A (zh) | 2023-10-10 |
| EP4259129A4 (en) | 2024-11-27 |
| IL303592A (en) | 2023-08-01 |
| WO2022125925A1 (en) | 2022-06-16 |
| JP2023553414A (ja) | 2023-12-21 |
| US20240009168A1 (en) | 2024-01-11 |
| EP4259129A1 (en) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
| BR112023021068A2 (pt) | Compostos, composições e métodos para tratar câncer | |
| MX2020007853A (es) | Composiciones farmaceuticas para el tratamiento de fibrosis quistica. | |
| EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
| PH12020500134A1 (en) | Dihydrooxadiazinones | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| BRPI0508540A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| MX2023013577A (es) | Composiciones de bismuto-tiol y metodos de uso. | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| PH12020550494A1 (en) | Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors | |
| EA201791321A1 (ru) | Составы ингибитора lfa-1 | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| BR112018073524A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição. | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| CO2022016754A2 (es) | Moléculas de fijación para el tratamiento de cáncer | |
| BR112022008183A2 (pt) | Formas de sal de um receptor de c5a de componente do complemento | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| CR20250181A (es) | Compuesto fungicida | |
| BR112021020027A2 (pt) | Compostos, composições e métodos | |
| BR112022024988A2 (pt) | Compostos e métodos para tratamento de infecções fúngicas | |
| CL2021001944A1 (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias |